Crescent Biopharma (NASDAQ:CBIO) Cut to “Sell” at Wall Street Zen

Wall Street Zen lowered shares of Crescent Biopharma (NASDAQ:CBIO) from a hold rating to a sell rating in a research note issued to investors on Saturday.

A number of other brokerages have also recently issued reports on CBIO. Wedbush initiated coverage on Crescent Biopharma in a research note on Monday, July 14th. They set an “outperform” rating and a $27.00 price objective for the company. Stifel Nicolaus initiated coverage on Crescent Biopharma in a research note on Wednesday, June 25th. They set a “buy” rating and a $28.00 price objective for the company. TD Cowen upgraded Crescent Biopharma to a “strong-buy” rating in a research note on Friday, June 20th. Finally, Lifesci Capital upgraded Crescent Biopharma to a “strong-buy” rating and set a $22.00 price objective for the company in a research note on Wednesday, June 18th. One investment analyst has rated the stock with a sell rating, two have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $25.67.

Crescent Biopharma Price Performance

CBIO opened at $11.84 on Friday. The company has a market capitalization of $231.47 million, a PE ratio of -0.34 and a beta of 1.51. Crescent Biopharma has a 52 week low of $11.06 and a 52 week high of $63.00.

Crescent Biopharma (NASDAQ:CBIO) last released its earnings results on Thursday, July 31st. The biopharmaceutical company reported ($4.93) EPS for the quarter, missing analysts’ consensus estimates of ($2.69) by ($2.24). As a group, research analysts expect that Crescent Biopharma will post -0.16 earnings per share for the current fiscal year.

Crescent Biopharma Company Profile

Crescent Biopharma, Inc operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.